Bettina E. Hansen

Active 1994–2026

212
Papers
27,215
Citations
94
h-index
200
i10-index

Citations

Citations per year for Bettina E. Hansen1996: 4 citations1997: 7 citations1998: 13 citations1999: 18 citations2000: 26 citations2001: 23 citations2002: 17 citations2003: 15 citations2004: 36 citations2005: 48 citations2006: 61 citations2007: 68 citations2008: 98 citations2009: 87 citations2010: 107 citations2011: 144 citations2012: 158 citations2013: 139 citations2014: 183 citations2015: 256 citations2016: 208 citations2017: 263 citations2018: 270 citations2019: 837 citations2020: 975 citations2021: 981 citations2022: 829 citations2023: 602 citations2024: 1,096 citations2025: 557 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,985 citing papers, 17.8% of this breakdownChina: 1,009 citing papers, 9% of this breakdownUnited Kingdom: 688 citing papers, 6.2% of this breakdownGermany: 636 citing papers, 5.7% of this breakdownItaly: 633 citing papers, 5.7% of this breakdownCanada: 582 citing papers, 5.2% of this breakdownFrance: 573 citing papers, 5.1% of this breakdownNetherlands: 544 citing papers, 4.9% of this breakdownSpain: 369 citing papers, 3.3% of this breakdownJapan: 320 citing papers, 2.9% of this breakdownAustralia: 290 citing papers, 2.6% of this breakdownSouth Korea: 286 citing papers, 2.5% of this breakdown
0%17.8%Other 29.1%

Fields

  • Medicine86.9%
  • Biochemistry, Genetics and Molecular Biology7%
  • Immunology and Microbiology3.4%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Computer Science0.3%
  • Engineering0.3%
  • Other1.4%

Topics

  • Liver Disease Diagnosis and Treatment12.8%
  • Hepatitis C virus research10.3%
  • Hepatitis B Virus Studies8.7%
  • Liver Diseases and Immunity5.5%
  • Liver Disease and Transplantation4.6%
  • Hepatocellular Carcinoma Treatment and Prognosis3.4%
  • Other54.7%

Coauthors

All papers

Open in search
  1. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Pruzanski, Д. А. Шапиро - New England Journal of Medicine 2016 cited by 1,108

  2. Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2024 cited by 159

  3. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine N. Manser, George Ν. Dalekos, Bertus Eksteen, Pietro Invernizzi, Christoph P. Berg, Gabi I. Kirchner, Christoph Sarrazin, Vincent Zimmer, Luca Fabris, Felix Braun, Marco Marzioni, Brian D. Juran, Karouk Said, Christian Rupp, Kalle Jokelainen, M Valle, Francesca Saffioti, Angela Cheung, Michael Trauner, Christoph Schramm, Roger W. Chapman, Tom H. Karlsen, Erik Schrumpf, Christian P. Strassburg, Michael P. Manns, Keith D. Lindor, Gideon M. Hirschfield, Bettina E. Hansen, Kirsten Muri Boberg - Gastroenterology 2017 cited by 523

  4. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2015 cited by 541

  5. Early Treatment with Pegylated Interferon Lambda for Covid-19

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher Kandel, Mia J. Biondi, Robert Kozak, Bettina E. Hansen, Muhammad Atif Zahoor, Paul Arora, Colin Hislop, Ingrid Choong, Jordan J. Feld, Edward J. Mills, Jeffrey S. Glenn - New England Journal of Medicine 2023 cited by 174

  6. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2014 cited by 489

  7. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2015 cited by 436

  8. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Hepatology 2019 cited by 277

  9. External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study

    Authors: , , , , , - Clinical Gastroenterology and Hepatology 2013 cited by 343

  10. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rachel Smith, Steve Flack, Victoria Mulcahy, Michael Trauner, Christopher L. Bowlus, Keith D. Lindor, Christophe Corpechot, David Jones, George Mells, Gideon M. Hirschfield, James Wason, Bettina E. Hansen, Richard Sturgess, Christopher G. Healey, Anton Gunasekera, Yiannis Kallis, Gavin Wright, Thiriloganathan Mathialahan, Richard J. Evans, Jaber Gasem, David Ramanaden, Emma Ward, Mahesh Bhalme, Paul Southern, James L. Maggs, Mohamed Yousif, George Mells, Brijesh Srivastava, Matthew Foxton, Carole Collins, Yash Prasad, Francisco Porras-Perez, Tom Yapp, Minesh Patel, Roland Ede, Martyn Carte, Konrad Koss, Prayman Sattianayagam, Charles Grimley, Jude Tidbury, Dina Mansour, Matilda Beckley, Coral Hollywood, John Ramag, Harriet Gordon, Joanne Ridpath, Bob Grover, George Abouda, Ian Rees, Mark Narain, Imroz Salam, Paul Banim, Debasish Das, Helen Matthews, Faiyaz Mohammed, Rebecca Jones, Sambit Sen, G. W. G. Bird, Martin Prince, Geeta Prasad, Paul Kitchen, John Hutchinson, Prakash C. Gupta, David Jones, Amir Shah, Subrata Saha, Katharine Pollock, Stephen Barclay, Natasha McDonald, Simon Rushbrook and 56 more - Gastroenterology 2022 cited by 101

  11. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

    Authors: , , , , - Journal of Hepatology 2015 cited by 495

  12. Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study

    Authors: , , , , , - The Lancet Respiratory Medicine 2020 cited by 223

  13. Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B

    Authors: , , , , , , , - Hepatology 2019 cited by 208

  14. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2021 cited by 187

  15. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis

    Authors: , , , , , , , , - Journal of Hepatology 2021 cited by 136

  16. Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

    Authors: , , , , , , , , , - Gastroenterology 2009 cited by 460

  17. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2020 cited by 138

  18. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

    Authors: , , , , , , , , - JHEP Reports 2021 cited by 114

  19. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The American Journal of Gastroenterology 2020 cited by 171

  20. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

    Authors: , , , , , , , , , , - Gut 2013 cited by 265

  21. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , D. Lorne Tyrrell, Jeffrey S. Glenn, Adam J. Gehring, Harry L.A. Janssen, Bettina E. Hansen - The Lancet Respiratory Medicine 2021 cited by 237

  22. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis

    Authors: , , , , , , , , , , , , , - Journal of Hepatology 2017 cited by 213

  23. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

    Authors: , , , , , , , , , , , - Journal of Hepatology 2020 cited by 141

  24. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Alimentary Pharmacology & Therapeutics 2019 cited by 116